Preliminary studies utilizing Platelet-Rich-Plasma (PRP) [ 26 ], anakinra (an interleukin-1 antagonist) [ 26 ] or apronitin (a MMP-inhibitor) [ 28 ] have produced encouraging results, suggesting that substances targeting IL-1β or inhibiting MMPs may be useful.